Bortezomib (BTZ) clinical trials

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

This study is testing a new drug called CC-220, sometimes on its own and sometimes with other standard cancer medicines, for people with multiple myeloma. It aims to find the right dose, see how safe it is, and if it helps treat the disease.